Geschäftsreise nach UK – Biotech

From 18 to 21 May 2026, in2newmarkets together with Life Science Integrates (LSI), on behalf of the Federal Ministry for Economic Affairs and Energy (BMWE), will organize a Trade Mission to UK focusing on Medical biotechnology. The trip is part of the Healthcare Export Initiative and will be carried out within the framework of the Market Entry Program for SMEs. The target group primarily consists of small and medium-sized German companies.

Why UK? Market opportunities

The UK market holds a leading position within Europe. In 2023, around 4% of the global biopharma market volume — equivalent to approximately €25.5 billion — was attributed to the United Kingdom. The following market segments are particularly relevant for German stakeholders:

• Technology Providers (e.g. AI platforms, digital solutions): German providers of AI-based platforms and health analytics systems will find strong potential here.
• CROs: Demand for preclinical and clinical research is growing, particularly in oncology, neuroscience, and rare diseases.
• CDMOs and CMOs: With the expansion of manufacturing capacities for cell and gene therapies, mRNA, and biologics, the need for experienced production partners is increasing — especially in clusters such as Stevenage, Oxford, and Cambridge.
• Therapeutics Developers: German developers of small and large molecules as well as cell and gene therapies benefit from UK programs such as the Cell and Gene Therapy Catapult and an innovation-friendly funding environment.
• Lab Equipment and Technology Providers: The modernization of UK research institutions creates opportunities for suppliers of analytical instruments, robotics, and bioprocess systems.
• Diagnostics: Growing investments in precision medicine and AI-driven diagnostics are generating demand for molecular and digital solutions.
• Testing Facilities (QA/QC): As production grows, so does the demand for quality assurance and GMP testing.